Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target
Kamal Mandal(University of California, San Francisco), Arun P. Wiita(University of California, San Francisco), Corynn Kasap(University of California, San Francisco), William C. Temple(UCSF Benioff Children's Hospital), Michael R. Hoopmann(Niedersächsisches Landesgesundheitsamt), Akul Naik(University of California, San Francisco), Bonell Patiño-Escobar(University of California, San Francisco), Melanie McMillan(University of California, San Francisco), Elliot Stieglitz(UCSF Benioff Children's Hospital), Veronica Steri(University of California, San Francisco), Fernando Salangsang(Novartis (Switzerland)), Paul Phojanakong(UCSF Helen Diller Family Comprehensive Cancer Center), Robert L. Moritz(Institute for Systems Biology), Sachdev S. Sidhu(University of Waterloo), Benjamin J. Huang(University of California, San Francisco), Gianina Wicaksono(University of California, San Francisco), Lan Huang(University of California, Irvine), Emilio Ramos(University of California, San Francisco), Juan A. Cámara(UCSF Helen Diller Family Comprehensive Cancer Center), Matthew A. Nix(University of California, San Francisco), Christian Ihling(University of Stuttgart), Andrea Sinz(Luther University), Victor Gavallos(University of California, San Francisco), Catherine C. Smith(University of California, San Francisco), Andrew D. Leavitt(University of California, San Francisco), Clinton Yu(University of California, Irvine), Jarrett J. Adams(University of Toronto), Maryna Gorelik(University of Toronto)
Cited by 2
Related Papers
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745